See the DrugPatentWatch profile for wegovy

Wegovy, a medication recently approved by the FDA for chronic weight management, can save money for patients in several ways.

First, by helping patients achieve and maintain a healthy weight, Wegovy can reduce the need for other medications and treatments associated with obesity-related conditions. These conditions include type 2 diabetes, hypertension, and dyslipidemia, which can require costly medications and treatments [1].

Second, Wegovy can potentially reduce the frequency of hospitalizations and medical procedures related to obesity and its comorbidities. This can lead to significant cost savings for patients, as hospital stays and procedures can be expensive [1].

Third, Wegovy's potential to improve patients' overall health and quality of life may result in reduced absenteeism from work and increased productivity, leading to financial benefits for patients [1].

Lastly, Wegovy's list price is comparable to other obesity medications on the market [2]. However, it is important to note that the actual cost to patients will depend on their insurance coverage and any negotiated discounts or rebates [2].

In summary, Wegovy can save money for patients by reducing the need for other medications and treatments, decreasing hospitalizations and medical procedures, improving productivity, and having a competitive list price.

Sources:
[1] DrugPatentWatch.com. (2021). Wegovy (semaglutide) for Obesity. Retrieved from <https://www.drugpatentwatch.com/obesity-treatments/wegovy-semaglutide/>
[2] Novo Nordisk. (2021). Wegovy™ (semaglutide) injection 2.4 mg. Retrieved from <https://www.wegovy.com/about-wegovy/how-wegovy-works>